LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Suletud

0.32

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	605K -15M
Müük	19M 40M
Kasumimarginaal	-37.72
Töötajad	105
EBITDA	155K -12M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. nov 2025

Turustatistika
By TradingEconomics
Turukapital	481K 83M
Eelmine avamishind	0.32
Eelmine sulgemishind	0.32

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. sept 2025, 23:56 UTC

Kuumad aktsiad

Stocks to Watch: FedEx, 22nd Century, Scholastic

18. sept 2025, 22:01 UTC

Suurimad hinnamuutused turgudel

22nd Century Group Shares Gain on Debt Repayment, New Capital

18. sept 2025, 20:51 UTC

Omandamised, ülevõtmised, äriostud

UPS Terminates Plan to Buy Estafeta

18. sept 2025, 20:31 UTC

Tulu

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18. sept 2025, 20:26 UTC

Tulu

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18. sept 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. sept 2025, 23:43 UTC

Market Talk

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18. sept 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

18. sept 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Cautious Mood -- Market Talk

18. sept 2025, 23:31 UTC

Market Talk

FedEx Says U.S. Demand Is Resilient -- Market Talk

18. sept 2025, 22:03 UTC

Tulu

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18. sept 2025, 22:01 UTC

Tulu

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18. sept 2025, 21:56 UTC

Tulu

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18. sept 2025, 21:54 UTC

Tulu

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18. sept 2025, 21:48 UTC

Tulu

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18. sept 2025, 21:47 UTC

Tulu

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18. sept 2025, 21:17 UTC

Tulu

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18. sept 2025, 21:07 UTC

Tulu

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18. sept 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. sept 2025, 20:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

18. sept 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

18. sept 2025, 20:22 UTC

Omandamised, ülevõtmised, äriostud

UPS Cites Inability of All Closing Conditions to Be Satisfied

18. sept 2025, 20:22 UTC

Omandamised, ülevõtmised, äriostud

United Parcel Service Terminates Plan to Buy Estafeta

18. sept 2025, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18. sept 2025, 20:18 UTC

Tulu

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18. sept 2025, 20:18 UTC

Tulu

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18. sept 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. sept 2025, 20:07 UTC

Tulu

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18. sept 2025, 20:03 UTC

Tulu

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.